Focus: Kuros Biosciences is a Swiss-headquartered medical device company founded in 2008 focused on bone regeneration and orthopedic surgery solutions. The company is publicly listed and operates across multiple surgical indications including spinal fusion, fracture repair, and degenerative disc disease.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
Kuros is a stage-appropriate fit for professionals seeking growth-phase device company exposure with orthopedic expertise, though limited job openings and early-stage pipeline carry execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Kuros Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Kuros Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Does ORIC (ORIC) Retaining Rinzimetostat Rights Hint At A High-Conviction, High-Risk Development Strategy? - simplywall.st
Does ORIC (ORIC) Retaining Rinzimetostat Rights Hint At A High-Conviction, High-Risk Development Strategy? simplywall.st
Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals (REGN) - simplywall.st
Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals (REGN) simplywall.st
WiseTech Global Stock and 2 Australian Shares Trading Below Estimated Fair Value - simplywall.st
WiseTech Global Stock and 2 Australian Shares Trading Below Estimated Fair Value simplywall.st
CSPC Pharmaceutical Group (SEHK:1093) Could Be 115% Below Fair Value Following Drug Approval - simplywall.st
CSPC Pharmaceutical Group (SEHK:1093) Could Be 115% Below Fair Value Following Drug Approval simplywall.st
Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative? simplywall.st
Chugai Pharmaceutical (TSE:4519) Stock Net Margin Strength Challenges Cost Pressure Concerns - simplywall.st
Chugai Pharmaceutical (TSE:4519) Stock Net Margin Strength Challenges Cost Pressure Concerns simplywall.st
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
BMP-7 mRNA delivered by Fibrin-CaP scaffolds activates osteogenic programs in vivo as evidenced by transcriptomic and proteomic analyses.
A single-arm retrospective feasibility study of biphasic calcium phosphate bone graft with submicron surface topography in anterior cervical discectomy and fusion (ACDF) procedures 6 months postoperative.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo